OUR PURPOSE PIONEERING SCIENCE COMMUNITY REPORTING 90 PROMOTING ENVIRONMENTAL SUSTAINABILITY BIOGEN 2021 YEAR IN REVIEW PATIENTS OUR PEOPLE ENVIRONMENT ANALYSIS Our product lifecycle Our approach Biosimilars can offer a range of benefits to patients and health systems, improving patient access to leading biologic therapies while also generating significant cost savings. Þ READ MORE IN PIONEERING SCIENCE As we work to expand our biosimilars portfolio, another way we can promote public health is by reducing environmental impact. 3 PRODUCTS – Benepali – Flixabi – Imraldi 4 COUNTRIES – France – Germany – Sweden – U.K. 6 PACKAGING OPTIONS – 1-pack – 2-pack – 4-pack – 5-pack – 6-pack – 12-pack 3 DELIVERY MECHANISMS – Pen – Prefilled syringe – Vial 1. Package design for therapy 2. Device materials 3. Upstream transport (device materials, packaging materials, packaging suppliers) 4. Packing energy (at Sharp & Grunenthal) 5. Distribution of finished products via refrigerated trucks 6. End-of-life of packaging & devices (recycling, disposal) 1. 2. 3. 4. 5. 6. Understanding the lifecycle of biosimilars We are mapping the lifecycle of a growing range of products to identify opportunities for reduced environmental impact from “cradle to grave.” This can provide actionable new insights into product impacts across materials, manufacturing, distribution and end-of-life issues. Elements included in our lifecycle analysis